Improvement of hepatic bioavailability as a new step for the future of statin

Archives of Medical Science

Volumn 11, Issue 2, 2015, Pages 406-410

  Petyaev, Ivan M ^a  

^a Lycotec Ltd   (United Kingdom)

Author keywords

Bioavailability; Cholesterol; Lycopene; Statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYCO SIMVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SOLUBILITY; ENZYME INHIBITION; HEPATIC AVAILABILITY; HUMAN; LIVER CELL; MOLECULAR WEIGHT; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT;

EID: 84928412156     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.50972     Document Type: Article

References (34)

1. Coyan FC, Loussouarn G. Cholesterol regulation of ion channels: crosstalk in proteins, crosstalk in lipids. Channels (Austin) 2013; 7: 415-6.
2. Poirier S, Mayer G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther 2013; 7: 1135-48.
3. Mark L, Paragh G, Karadi I, Reiber I, Pados G, Kiss Z. How can we further improve the LDL-cholesterol target level achievement rate based on the Hungarian MULTI GAP 2011 study results and considering the new European dyslipidemia guidelines? Arch Med Sci 2012; 8: 608-13.
4. Webb J, Gonna H, Ray KK. Lipid management: maximising reduction of cardiac risk. Clin Med 2013; 13: 618-20.
5. Katsiki N, Mikhailidis DP, Athyros VG, Hatzitolios AI, Karagiannis A, Banach M. Are we getting to lipid targets in real life? Arch Med Sci 2010; 6: 639-41.
6. Aronow WS. Peripheral arterial disease of the lower extremities. Arch Med Sci 2012; 8: 375-88.
7. Sorci-Thomas MG, Thomas MJ. Why targeting HDL should work as a therapeutic tool, but has not. J Cardiovasc Pharmacol 2013; 62: 239-46.
8. Hennekens CH, Drowos J. Statins: the high risks of discontinuation and large benefits of continuation. Arch Med Sci 2011; 7: 931-2.
9. Rizzo M, Battista Rini G. Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia. Arch Med Sci 2011; 7: 5-7.
10. Poli G, Biasi F, Leonarduzzi G. Oxysterols in the pathogenesis of major chronic diseases. Redox Biol 2013; 1: 125-30.
11. Parhofer KG. Update: clinical lipidology. MMW Fortschr Med 2013; 155: 49-52; quiz 53-4.
12. Sharpe LJ, Brown AJ. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). J Biol Chem 2013; 288: 18707-15.
13. Allian-Sauer MU, Falko JM. New treatments on the horizon for familial hypercholesterolemia. Expert Rev Cardiovasc Ther 2012; 10: 1227-37.
14. Tiwari R, Pathak K. Statins therapy: a review on conventional and novel formulation approaches. J Pharm Pharmacol 2011; 63: 983-98.
15. Chen GP, Yao L, Lu X, Li L, Hu SJ. Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutarylcoenzyme A reductase expression and activity in spontaneously hypertensive rats. Acta Pharmacol Sin 2008; 29: 1181-6.
16. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423-29.
17. Banach M, Aronow WS, Serban C, et al. Lipids, blood pressure and kidney update 2014. Pharmacol Res 2015; 95-96C: 111-25.
18. Kiss Z, Nagy L, Reiber I, et al. Persistence with statin therapy in Hungary. Arch Med Sci 2013; 9: 409-17.
19. Olson EA, Hainsworth DP, Davis G, Hagan JC. Eye on statins: a comprehensive review. Mo Med 2013; 110: 344-8.
20. Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11: 1-23.
21. Huddy K, Dhesi P, Thompson PD. Do the frequencies of adverse events increase, decrease, or stay the same with long-term use of statins? Curr Atheroscler Rep 2013; 15: 301-8.
22. Hohenegger M. Drug induced rhabdomyolysis. Curr Opin Pharmacol 2012; 12: 335-40.
23. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403-14.
24. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117-25.
25. Nezasa K, Higaki K, Matsumura T, et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002; 30: 1158-63.
26. Shirasaka Y, Suzuki K, Nakanishi T, Tamai I. Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide. Pharm Res 2010; 27: 2141-9.
27. Carotenoid Particles And Uses Thereof. GB Patent Application No. 1101669.8, PCT/GB2012/000075, 25.01.2012.
28. Patel D, Sawant KK. Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs. Curr Drug Deliv 2009; 6: 419-24.
29. Bravo E, Napolitano M. Mechanisms involved in chylomicron remnant lipid uptake by macrophages. Biochem Soc Trans 2007; 35: 459-63.
30. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 2013; 62: 479-91.
31. Chakravarti R, Sahai V. Compactin - a review. Appl Microbiol Biotechnol 2004; 64: 618-24.
32. Roth BD. The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Prog Med Chem 2002; 40: 1-22.
33. Ling H, Burns TL, Hilleman DE. Novel strategies for managing dyslipidemia: treatment beyond statins. Postgrad Med 2012; 124: 43-54.
34. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? J Med Sci Monit 2009; 15: MS1-5.